Predictive Oncology (POAI 16.91%), an organization targeted on AI-driven drug discovery and oncologic assay commercialization, launched its earnings for the quarter ended June 30, 2025, on August 14, 2025. GAAP income fell 96% to $2,682 in Q2 2025 from $67,255 in Q2 2024, as gross sales of its tumor-specific 3D fashions and kits almost disappeared. There have been no analyst estimates obtainable for comparability. Working losses narrowed to $(1,978,895) (GAAP) from $(2,456,669) within the prior-year interval, reflecting value financial savings however not any business turnaround. The quarter noticed expanded advertising efforts, with elevated spending on digital initiatives, however with minimal GAAP income of $2,682 and declining money (from $611,822 as of December 31, 2024 to $506,078 as of June 30, 2025), the monetary image stays strained.
MetricQ2 2025Q2 2024Y/Y ChangeEPS (GAAP)$(0.22)$(0.53)58.5percentRevenue$2,682$67,255(-96.0 %)Loss from Persevering with Operations$(1,978,895)$(2,456,669)-19.5 %Basic & Administrative Expense$1,875,655$1,825,1742.8 %Money & Money Equivalents$506,078as of Jun 30, 2025$611,822as of Dec 31, 2024(17.3 %)
Overview of Predictive Oncology’s Enterprise and Present Focus
Predictive Oncology operates on the intersection of synthetic intelligence and oncology, utilizing superior software program and a proprietary tumor biobank to help biopharma companions in most cancers drug discovery. The corporate leverages its AI platform, referred to as PEDAL, and a group of greater than 150,000 affected person tumor samples to construct predictive fashions that establish and repurpose drug candidates for a wide range of cancers.
Not too long ago, the corporate has targeted on transitioning from legacy choices, corresponding to 3D tumor fashions and kits, in the direction of new pipelines centered on AI-powered drug discovery and commercializing proprietary assays. Key priorities embrace increasing the attain of ChemoFx, its major live-cell drug response assay, and capitalizing on its biobank by constructing value-added partnerships.
Quarter in Element: Metrics, Product Strikes, and Monetary Shifts
Throughout Q2 2025, Predictive Oncology’s GAAP income contracted dramatically, primarily resulting from a decline in gross sales of 3D tumor fashions and kits. GAAP income fell from $67,255 in Q2 2024 to simply $2,682, a 96% drop. Administration attributed the discount to decrease gross sales exercise. Though total working losses narrowed to $(1,978,895) (GAAP), this enchancment was primarily resulting from ongoing value containment quite than any restoration in gross sales or new buyer traction.
Working bills rose modestly, up 5% within the three months ended June 30, 2025, in comparison with the prior yr. Basic and administrative bills (GAAP) elevated 2.8% to $1,875,655 in Q2 2025 from $1,825,174 in Q2 2024. Gross sales and advertising bills (GAAP) doubled to $268,959 in Q2 2025 from $134,186 in Q2 2024, with administration pointing to new digital advertising initiatives to assist the approaching U.S. and European ChemoFx launches.
The core focus for the quarter was advancing the corporate’s AI-driven drug discovery efforts. Administration highlighted the PEDAL platform’s means to mine publicly obtainable drug information, ensuing within the identification of three most cancers remedy candidates (Afuresertib for breast most cancers, Alisertib and Entinostat for colon most cancers) for potential repurposing. All exercise remained on the preclinical stage, with no partnerships or milestone funds reported in the course of the quarter.
ChemoFx, a validated live-cell testing assay designed to foretell tumor responses to chemotherapy, remained central to the strategic plan. The corporate continued preparations for a broader U.S. business rollout and a deliberate preliminary European launch, each focused for the fourth quarter of 2025. Administration offered no particular information on pilot program outcomes, contract awards, or preliminary buyer uptake for ChemoFx in the course of the quarter.
Predictive Oncology did obtain a technical milestone in growing two 3D liver toxicity fashions solely for diagnostics agency Labcorp (NYSE:LH). Nevertheless, this achievement had no reported impression on present income, and administration didn’t disclose the phrases or income contribution from the challenge. The shortage of clear uptake for brand spanking new scientific platforms stresses the problem in turning early-stage scientific growth into business merchandise.
On the financing entrance, the corporate raised roughly $586,000 in Q2 2025 by way of a personal placement and an at-the-market inventory program. It additionally executed a standby fairness buy settlement of as much as $10 million with Yorkville Advisors World, offering short-term entry to capital as wanted. Money available, nonetheless, continued to erode, declining to $506,078 at quarter-end. Complete stockholders’ deficit (GAAP) worsened sharply from $202,610 at December 31, 2024, to $1,653,400 at June 30, 2025, underscoring the necessity for additional exterior funding to maintain operations.
The biobank stays a strategic asset, with greater than 150,000 affected person tumor samples. Administration describes it as a aggressive benefit within the AI-driven oncology house. No new licensing or partnership income linked to the biobank was disclosed.
Wanting Forward: Steerage and Ahead Priorities
The administration workforce didn’t present monetary steering for the rest of fiscal 2025 or for fiscal 2026. Management acknowledged that significant income era is predicted to start in 2026 or later, with a near-term deal with the profitable launch and adoption of ChemoFx in each U.S. and European markets. No quantified targets for income, revenue, or money runway have been shared within the quarter’s launch or commentary.
Buyers ought to monitor the corporate’s means to safe further funding. Different key factors to observe in coming quarters are developments within the deliberate European launch, enlargement into new oncology indications for ChemoFx, progress in pipeline drug repurposing candidates, and any updates concerning ongoing merger discussions with Renovaro (NASDAQ:RNRO). The corporate doesn’t at the moment pay a dividend.
Income and internet revenue introduced utilizing U.S. typically accepted accounting rules (GAAP) until in any other case famous.
